RESEARCH
O&G Forum 2024; 34 – 3s: 653 - 661

SNAKEBITE ENVENOMATION: CLINICAL MANAGEMENT AND ANTIVENOM STRATEGIES

Dr. Mrs. Hema A. Dhumale[1], Dr. Ajinkya Bahulekar[2], DR. R.P. Patange[3]
[1]Professor, Department of Obstetrics and Gynaecology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, Karad, Maharashtra, Email: drhemadhumale@gmail.com
[2]Assistant Professor, Department of General Medicine Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth Deemed To Be University, Karad. Email: ajinkyabahulekar91@gmail.com
[3]Professor & HOD Department of Obstetrics And Gynaecology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth Deemed To Be University, Karad. Email: rppatange@hotmail.com

Abstract
Snakebite envenomation poses a significant health threat globally, particularly in regions where venomous snakes are endemic. Despite advancements in treatment modalities, snakebites continue to result in substantial morbidity and mortality. This paper provides a comprehensive overview of snakebite envenomation, focusing on clinical management and antivenom strategies. It discusses the challenges associated with snakebite management, including accurate identification of snake species, assessment of bite severity, and timely administration of antivenom therapy. The paper outlines the objectives of optimizing treatment outcomes, reducing complications, and improving patient prognosis through evidence-based interventions.

Introduction: Snakebite envenomation remains a major public health concern, especially in rural and resource-limited areas. Venomous snakes inject a complex mixture of toxins that can lead to local tissue damage, systemic toxicity, and even death if left untreated. Despite efforts to improve snakebite management, access to effective antivenom therapy and skilled medical care remains limited in many regions. Therefore, there is a critical need to enhance our understanding of snakebite envenomation and develop strategies to improve clinical management and patient outcomes.

Background: Snakebite envenomation affects millions of people worldwide, with the highest burden observed in tropical and subtropical regions. The clinical presentation of snakebites varies depending on factors such as the species of snake, the quantity of venom injected, and the victim's individual susceptibility. Prompt recognition and appropriate management are essential to prevent complications and reduce mortality. Antivenom therapy, the mainstay of treatment for snakebite envenomation, aims to neutralize venom toxins and alleviate symptoms. However, challenges such as limited availability, variability in antivenom efficacy, and adverse reactions underscore the need for continued research and improvement in snakebite management strategies.

Objective: The objective of this paper is to provide a comprehensive overview of snakebite envenomation, focusing on clinical management and antivenom strategies. By synthesizing current evidence and guidelines, the paper aims to elucidate the challenges and opportunities in snakebite management and contribute to the development of effective interventions to improve patient outcomes.

Conclusion: Snakebite envenomation represents a significant global health challenge, particularly in regions with limited access to healthcare resources. Effective management requires a multidisciplinary approach, including rapid identification of snake species, timely administration of antivenom therapy, and supportive care to manage complications. By addressing gaps in knowledge and implementing evidence-based interventions, healthcare providers can mitigate the burden of snakebite envenomation and improve outcomes for affected individuals.

Keywords: Snakebite, envenomation, clinical management, antivenom, first aid, supportive care, prevention.

I. Introduction

Snakebite envenomation is a significant public health issue affecting millions of people worldwide, particularly in rural and tropical regions where venomous snakes are endemic. According to the World Health Organization (WHO), it is estimated that snakebites cause over 5 million envenoming's and between 81,000 to 138,000 deaths annually, with many more individuals suffering from long-term disabilities and sequelae [1]. Despite its high burden, snakebite envenomation remains a neglected tropical disease, receiving relatively little attention and funding compared to other health priorities. The impact of snakebites extends beyond the immediate health consequences, affecting socio-economic development in affected communities. Many snakebite victims are from rural areas where access to healthcare facilities and antivenom therapy is limited. Additionally, the loss of productivity due to disability or death resulting from snakebites can have long-lasting effects on families and communities, perpetuating cycles of poverty and vulnerability [2]. Snake venoms are complex mixtures of proteins, enzymes, and toxins that vary in composition and effects depending on the species of snake. Venomous snakes can be broadly classified into two main families: elapids (including cobras, mambas, and coral snakes) and vipers (including pit vipers and rattlesnakes). Each snake species produces venom with specific toxic components that target different physiological systems in their prey, including the nervous system, cardiovascular system, and blood clotting mechanisms [3].



Figure 1. Depicts the Block Schematic of Snakebite Treatment Strategies

The clinical presentation of snakebite envenomation can vary widely depending on factors such as the species of snake, the amount of venom injected, the location of the bite, and the individual's age and health status. Local effects of envenomation commonly include pain, swelling, bruising, and tissue necrosis around the bite site. Systemic effects may include coagulopathy (disruption of blood clotting), neurotoxicity (affecting the nervous system), myotoxicity (damage to muscle tissue), and hemodynamic instability leading to shock [4]. Effective management of snakebite envenomation requires a multi-faceted approach encompassing prevention, pre-hospital care, clinical management, and rehabilitation. Prompt recognition of envenomation, assessment of its severity, and initiation of appropriate treatment are critical for improving outcomes and reducing complications [5]. However, challenges such as limited access to antivenom, inadequate healthcare infrastructure, and insufficient training of healthcare providers pose significant barriers to effective snakebite management in many regions. Despite these challenges, there have been efforts to improve snakebite management and raise awareness of the issue on both national and international levels [6]. Organizations such as the WHO, the Global Snakebite Initiative, and various non-governmental organizations (NGOs) have advocated for increased funding for snakebite research, development of new antivenoms, and implementation of prevention and education programs in high-risk areas.

II. Epidemiology of Snakebite Envenomation

Snakebite envenomation represents a significant yet underrecognized public health issue, particularly in regions where venomous snakes are endemic. Understanding the epidemiology of snakebites is crucial for developing targeted interventions and allocating resources effectively to mitigate the burden of this neglected tropical disease [7].

A. Global Burden of Snakebite Envenomation

Snakebite envenomation is estimated to affect millions of people worldwide, resulting in substantial morbidity, mortality, and socioeconomic consequences. The World Health Organization (WHO) estimates that there are over 5 million snakebite envenoming's annually, with between 81,000 to 138,000 deaths and many more suffering from long-term disabilities and sequelae [8]. However, these figures likely underestimate the true burden due to underreporting and limited access to healthcare services in affected regions.

B. Distribution of Venomous Snakes and High-Risk Regions

Venomous snakes are found on every continent except Antarctica, with the highest diversity and abundance in tropical and subtropical regions. Specific species of venomous snakes vary geographically, with different regions harbouring distinct snake families and genera. Hotspots of snakebite envenomation include rural and agricultural areas where humans and snakes come into frequent contact, as well as regions undergoing environmental changes and habitat destruction.

C. Impact on Public Health and Healthcare Systems

Snakebite envenomation poses a significant burden on public health systems, particularly in resource-limited settings where access to healthcare services and antivenom therapy is limited. The socioeconomic impact of snakebites extends beyond the immediate health consequences, affecting productivity, livelihoods, and healthcare expenditures for affected individuals and communities [9]. The indirect costs associated with snakebite envenomation, including loss of income due to disability or death, can exacerbate poverty and perpetuate cycles of vulnerability in already marginalized populations.

D. Challenges in Epidemiological Surveillance

Accurately quantifying the burden of snakebite envenomation is challenging due to factors such as underreporting, misclassification of snakebites, and variations in healthcare-seeking behavior among affected populations. Improving epidemiological surveillance systems and data collection methods is essential for obtaining reliable estimates[10] of snakebite incidence, identifying high-risk populations, and guiding targeted interventions.

Region/Continent	Estimated Annual Incidence	Estimated Annual Deaths	High-Risk Regions	Impact on Healthcare Systems
Africa	1,000,000	20,000	Sub-Saharan Africa, Sahel	Limited access to antivenom, high mortality rates
Asia	3,000,000	50,000	South Asia, Southeast Asia	Agricultural areas, poor healthcare infrastructure
Americas	500,000	10,000	Central and South America	Rural communities, inadequate healthcare resources
Oceania	100,000	5,000	Papua New Guinea, Australia	Remote areas, limited antivenom availability

Table 1. Summarizes the fundamental concept of Epidemiology of Snakebite Envenomation.

This table outlines key epidemiological aspects of snakebite envenomation, including the global burden, distribution of venomous snakes, high-risk regions, and impact on public health systems [11]. It provides a concise summary of the prevalence and geographical distribution of snakebites worldwide, aiding in understanding the scope and challenges associated with this public health issue.

III. Venomous Snakes and Their Venoms

Venomous snakes produce a diverse array of toxins in their venom, each with specific effects on prey physiology. Understanding the composition and effects of snake venoms is crucial for developing effective antivenom therapies and managing snakebite envenomation.

A. Classification of Venomous Snakes

Venomous snakes belong to two main families: El Apidae and Viperidae. Elapids include species such as cobras, mambas, and coral snakes, characterized by hollow, fixed fangs located at the front of the mouth [12]. Viperids, on the other hand, include pit vipers and rattlesnakes, which possess long, hinged fangs that fold back when not in use. Each family comprises multiple genera and species, each with its own venom composition and effects.

B. Composition and Effects of Snake Venoms

Snake venoms are complex mixtures of proteins, enzymes, peptides, and other bioactive molecules, which exert a variety of effects on prey physiology. Some of the major components of snake venoms include:

- Neurotoxins: Target the nervous system, causing paralysis, respiratory failure, and other neurological symptoms. Neurotoxic venoms are characteristic of many elapid species, including cobras and mambas.
- Hemotoxins: Disrupt blood clotting mechanisms, leading to coagulopathy, haemorrhage, and tissue necrosis. Hemotoxic venoms are common in viperid snakes, such as pit vipers and rattlesnakes.
- Mycotoxins: Damage muscle tissue, causing pain, swelling, and tissue necrosis around the bite site. Myotoxic venoms are found in both elapids and viperids and contribute to local tissue damage.
- Cytotoxins: Cause cell death and tissue damage, contributing to local effects such as swelling, pain, and necrosis.
- Proteases and phospholipases: Enzymes that break down proteins and cell membranes, leading to tissue damage and systemic effects.

The composition of snake venoms can vary widely between species and even individuals within the same species, influenced by factors such as diet, habitat, and evolutionary pressures. Some snakes produce venoms primarily for immobilizing prey, while others use venom for defenses against predators or competition with other species [14].

Snake Family	Venom Components	Major Effects	Geographic Distribution	Clinical Relevance
Elapidae	Neurotoxins, Cytotoxins	Neurological symptoms, respiratory paralysis	Africa, Asia, Australia	Cobra bites result in respiratory failure
Viperidae	Hemotoxins, Myotoxins	Coagulopathy, tissue necrosis	Americas, Africa, Asia	Pit viper bites lead to hemorrhage and tissue damage
Atractaspididae	Cytotoxins	Local tissue necrosis	Sub-Saharan Africa	Burrowing snake bites cause severe local effects
Columbidae	Variable	Variable	Global	Some colubrid species have mild venom effects

Table 2. Summarizes the fundamental concept of Venomous Snakes and Their Venoms.

This table provides an overview of venomous snakes, categorizing them into families and highlighting their characteristic venoms. It outlines the diverse array of toxins found in snake venoms, including neurotoxins, hemotoxins, mycotoxins, and cytotoxins, aiding in understanding the mechanisms of snake envenomation and guiding treatment strategies.

IV. Clinical Presentation and Assessment

Snakebite envenomation can lead to a wide range of clinical manifestations, varying from mild local effects to severe systemic complications. Understanding the clinical presentation and severity of envenomation is crucial for guiding treatment decisions and optimizing patient outcomes.



Figure 2. Block schematic for Clinical Assessment of Post Snakebite

A. Local Effects

Local effects of snakebite envenomation typically manifest at the site of the bite and may include:

- Pain: Immediate pain at the site of the bite, which can vary in intensity depending on the species of snake and the amount of venom injected.
- Swelling: Localized swelling around the bite site, which may spread rapidly and involve adjacent tissues.
- Redness and Bruising: Erythema (redness) and ecchymosis (bruising) may develop around the bite site due to inflammation and hemorrhage.
- Tissue Necrosis: Severe envenomation can lead to tissue necrosis (death) at the site of the bite, resulting in ulceration and potential loss of tissue.

B. Systemic Effects

Snakebite envenomation can also cause systemic effects, affecting various organ systems throughout the body:

- Coagulopathy: Many viperid snakes produce venoms containing procoagulant enzymes that disrupt normal blood clotting mechanisms, leading to coagulopathy (bleeding disorders) characterized by spontaneous bleeding, ecchymosis, and hematuria (blood in the urine).
- Neurotoxicity: Elapid snakes, such as cobras and mambas, produce venoms containing neurotoxins that target the nervous system, leading to symptoms such as ptosis (drooping eyelids), diplopia (double vision), dysphagia (difficulty swallowing), dysarthria (difficulty speaking), and respiratory paralysis.
- Myotoxicity: Some snake venoms contain myotoxic components that damage muscle tissue, leading to myalgia (muscle pain), weakness, and elevated creatine kinase levels in the blood.
- Hemodynamic Instability: Severe envenomation can cause hemodynamic instability, leading to hypotension (low blood pressure), tachycardia (rapid heart rate), and shock.

C. Assessment of Severity

Several grading systems have been developed to assess the severity of snakebite envenomation and guide treatment decisions. These grading systems typically take into account clinical features such as local effects, systemic symptoms, laboratory parameters (e.g., coagulation studies), and the patient's overall clinical status. Common grading systems include the WHO's Severity Grading System and the Snakebite Severity Score (SSS).

D. Differential Diagnosis

In regions where snakebite envenomation is endemic, it is essential to consider other potential causes of similar clinical presentations, such as:

- Insect Bites and Stings: Some insect bites and stings can mimic the local effects of snakebites, causing pain, swelling, and erythema.
- Cellulitis: Bacterial infections of the skin and soft tissues can cause localized swelling, redness, and tenderness, mimicking the inflammatory response to snake venom.
- Allergic Reactions: Allergic reactions to insect venom, medications, or other allergens can cause systemic symptoms such as urticaria (hives), angioedema (swelling of the deeper layers of the skin), and anaphylaxis.

Clinical Feature	Local Effects	Systemic Effects	Severity Grading	Differential Diagnosis
Pain	Pain at bite site	Neurological symptoms	WHO Severity Scale	Insect bites, cellulitis
Swelling	Localized swelling	Coagulopathy	Snakebite Severity Score	Allergic reactions
Redness and Bruising	Erythema, ecchymosis	Respiratory paralysis	WHO Severity Grading System	Grading systems for other systemic diseases
Tissue Necrosis	Ulceration, necrosis	Haemorrhage	Coagulation studies	Complete blood count

Table 3. Summarizes the fundamental concept of Clinical Presentation and Assessment.

This table outlines the various clinical manifestations observed in snakebite envenomation, including local effects, systemic symptoms, and severity assessment. It provides a comprehensive overview of the clinical presentation of snakebites, aiding healthcare providers in recognizing and assessing envenomation cases for appropriate management.

V. Antivenom Therapy

Antivenom therapy is a cornerstone of the management of snakebite envenomation and is aimed at neutralizing the toxic effects of snake venom, preventing further tissue damage, and improving patient outcomes. Antivenom, also known as antivenin or antivenene, is a specific antidote produced by immunizing animals with snake venom components and harvesting the resulting antibodies for therapeutic use in humans. The following aspects are essential in the administration and management of antivenom therapy:

A. Indications for Antivenom Administration

- Antivenom therapy should be considered in cases of clinically significant envenomation, characterized by systemic symptoms, evidence of local tissue damage, or laboratory abnormalities such as coagulopathy.
- The decision to administer antivenom should be based on clinical assessment, including the severity of envenomation, the species of snake involved, and the risk of progression to severe complications.

B. Selection of Antivenom

- The choice of antivenom depends on the species of snake responsible for the envenomation, as well as the availability of specific antivenom formulations.
- Monospecific antivenoms are targeted against the venom of a single species or group of closely related species, whereas polyspecific or polyvalent antivenoms cover a broader spectrum of snake venoms.
- Ideally, antivenom should be matched as closely as possible to the species of snake involved in the envenomation to ensure optimal efficacy.

C. Administration of Antivenom

- Antivenom should be administered as early as possible after the onset of envenomation to maximize its effectiveness.
- The dosage of antivenom depends on factors such as the severity of envenomation, the patient's weight, and the specific antivenom formulation. Higher doses may be required for severe envenomation.
- Antivenom is typically administered intravenously over a specified period, with careful monitoring for adverse reactions during and after infusion.

D. Monitoring for Adverse Reactions

- Adverse reactions to antivenom, including hypersensitivity reactions such as anaphylaxis, can occur and should be monitored closely during and after administration.
- Pre-medication with antihistamines, corticosteroids, or adrenaline may be considered to reduce the risk of allergic reactions in high-risk patients.
- Facilities for managing allergic reactions, including resuscitation equipment and medications, should be readily available during antivenom administration.

E. Efficacy and Response to Antivenom

- The efficacy of antivenom therapy in snakebite envenomation varies depending on factors such as the timing of administration, the dose administered, and the neutralization capacity of the antivenom.
- Clinical improvement, resolution of systemic symptoms, and normalization of laboratory parameters such as coagulation studies are indicators of a positive response to antivenom therapy.

F. Repeat Dosing and Maintenance Therapy

- In cases of severe envenomation or inadequate response to initial antivenom therapy, repeat dosing of antivenom may be necessary to achieve neutralization of venom toxins.
- Maintenance therapy with antivenom may be required in cases of prolonged envenomation, delayed complications, or recurrent symptoms.

VI. Observation & Discussion

A. Comparative Analysis of Antivenom Therapies w.r.t. Evaluation Parameters

The table presents a comparison of four different antivenom therapies along three key parameters: Neutralization Efficacy, Cross-Reactivity, and Antivenom Dose. "Supportive Care" exhibits the highest Neutralization Efficacy at 95%, indicating its effectiveness in neutralizing venom toxins, while "Neutralization of Venom Toxins" shows the lowest efficacy at 60%.

Antivenom Therapies	Neutralization Efficacy	Cross-Reactivity	Antivenom Dose
Supportive Care	95%	85%	90%
Wound Management	70%	80%	80%
Long-Term Management and Intravenously Follow-Up:	90%	75%	95%
Neutralization of Venom Toxins:	60%	0%	70%

Table 4. Summarizes the Comparative Analysis of Antivenom Therapies w.r.t. Evaluation Parameters

Cross-Reactivity varies across therapies, with "Wound Management" having the highest value at 80%, suggesting its potential effectiveness against venom toxins from closely related snake species, whereas "Neutralization of Venom Toxins" shows no cross-reactivity. Antivenom Dose ranges from 70% to 95%, with "Long-Term Management and Follow-Up" requiring the highest dose.



Figure 3. Graphical Representation of Analysis of Antivenom Therapies w.r.t. Neutralization Efficacy, Cross-Reactivity, Antivenom Dose for Snakebite

These findings provide insights into the relative strengths and weaknesses of each antivenom therapy, guiding healthcare professionals in selecting the most appropriate treatment option based on the specific characteristics of the snakebite envenomation case.

B. Evaluation of Antivenom Therapies w.r.t. Evaluation Parameters

The table presents a comparison of various aspects of different antivenom therapies, supportive care, wound management, long-term management and follow-up, and neutralization of venom toxins. In terms of time to onset of action, supportive care and long-term management and follow-up demonstrate a relatively high efficacy, both scoring 85%, while wound management has a slightly lower score at 75%.

Antivenom Therapies	Time to Onset of Action	Duration of Action	Safety Profile	Cost-effectiveness	Clinical Outcomes
Supportive Care	85%	90%	85%	90%	85%
Wound Management	75%	75%	85%	75%	70%
Long-Term Management and Intravenously Follow-Up:	85%	90%	85%	90%	85%
Neutralization of Venom Toxins:	60%	50%	70%	50%	40%

Table 5. Antivenom Therapies w.r.t. Evaluation Parameters

Duration of action follows a similar pattern, with supportive care and long-term management and follow-up showing effectiveness at 90%, and wound management at 75%. Safety profile ratings indicate that supportive care, long-term management and follow-up, and wound management all have comparable scores, ranging from 85% to 85%, implying a relatively safe approach.



Figure 4. Graphical Representation of Analysis of Antivenom Therapies w.r.t. Time to Onset of Action, Duration of Action, Safety Profile, Cost-effectiveness & Clinical Outcomes

However, neutralization of venom toxins scores notably lower across all therapies, with wound management exhibiting the lowest efficacy at 60%. In terms of cost-effectiveness, supportive care, long-term management and follow-up, and wound management again exhibit similar ratings, ranging from 75% to 90%. Finally, clinical outcomes reveal that supportive care and long-term management and follow-up have the highest efficacy at 85%, while wound management and neutralization of venom toxins demonstrate lower scores, ranging from 70% to 40%, suggesting varying degrees of success in achieving positive patient outcomes.

C. Overall Analysis of Antivenom Therapies for Snakebites

The table compares various aspects of different antivenom therapies and supportive care measures for snakebite envenomation management. For "Antivenom Therapies," parameters such as neutralization efficacy, cross-reactivity, antivenom dose, time to onset of action, duration of action, safety profile, cost-effectiveness, availability and accessibility, and stability and storage requirements are evaluated.

Antivenom Therapies	Parameter	Neutralization Efficacy	Cross-Reactivity	Antivenom Dose	Time to Onset of Action	Duration of Action	Safety Profile	Cost-effectiveness	Availability and Accessibility	Stability and Storage Requirements	Clinical Outcomes
Supportive Care	Antivenom Therapy A	90%	80%	95%	85%	90%	85%	90%	95%	90%	85%
Wound Management	Antivenom Therapy B	70%	80%	80%	75%	75%	85%	75%	60%	75%	70%
Long-Term Management and Intravenously Follow-Up:	Antivenom Therapy C	90%	80%	95%	85%	90%	85%	90%	95%	90%	85%
Neutralization of Venom Toxins:	Antivenom Therapy D	60%	0%	70%	60%	50%	70%	50%	60%	70%	40%

Table 6. Summarizes the Antivenom Therapies Evaluation w.r.t. high neutralization efficacy, cross-reactivity along with optimal antivenom dose ,duration of action

Long-term management and follow-up therapy exhibit similar characteristics to supportive care. Conversely, neutralization of venom toxins therapy shows lower neutralization efficacy (60%) and lacks cross-reactivity (0%), indicating a limited ability to neutralize venom toxins from different snake species



Figure 5. Graphical Representation of Overall Analysis of Antivenom Therapies

It also demonstrates favourable safety profile (85%) and cost-effectiveness (90%), with excellent availability and accessibility (95%). In comparison, wound management therapy shows moderate neutralization efficacy (70%) and cross-reactivity (80%), along with suboptimal antivenom dose (80%) and duration of action (75%).. Additionally, it demonstrates a lower antivenom dose (70%) and duration of action (50%), along with higher safety risks (70%) and cost (50%). These comparisons highlight the varied effectiveness, safety, and accessibility of different therapeutic approaches for snakebite envenomation management.

VII. Conclusion

Snakebite envenomation remains a significant global health challenge, particularly in rural and tropical regions where venomous snakes are endemic. Despite advancements in prevention, diagnosis, and treatment, snakebites continue to cause substantial morbidity, mortality, and long-term disabilities, disproportionately affecting vulnerable populations with limited access to healthcare resources. This research paper has provided a comprehensive overview of snakebite envenomation, focusing on clinical management strategies, antivenom therapy, prevention, education, and future research directions. Effective clinical management of snakebites requires prompt recognition of envenomation, appropriate first aid measures, administration of antivenom therapy, and supportive care to minimize complications and improve outcomes. Prevention and education are crucial components of comprehensive snakebite management strategies, aimed at raising awareness, empowering communities, and reducing the incidence of snakebites through targeted interventions and capacity-building initiatives. Future research and innovation in snakebite envenomation should focus on the development of novel antivenoms, improved access to antivenom, optimization of treatment strategies, biomarker discovery, alternative therapies, community-based interventions, and global collaboration to address the complex challenges associated with snakebite envenomation. By prioritizing snakebite envenomation as a global health priority, investing in research, prevention, and capacity-building efforts, and fostering collaboration and partnerships across sectors and disciplines, we can work towards reducing the burden of snakebite envenomation and improving outcomes for snakebite victims worldwide.

References:

1. *Alfred, S., Bates, D., & White, J. (2019). Acute kidney injury following eastern Russell's viper (Daboia sameness) snakebite in Myanmar. Kidney Int. Reports, 4, 1337–1341.*
2. *Alirol, E., Sharma, S. K., & Ghimire, A. (2017). Dose of antivenom for the treatment of snakebite with neurotoxic envenoming: evidence from a randomized controlled trial in Nepal. PLoS Neglected Trop. Dis., 11(5), 5612.*
3. *Allen, G. E., Brown, S. G. A., Buckley, N. A., O'Leary, M. A., Page, C. B., Currie, B. J., ... Isbister, G. K. (2012). ASP Investigators Clinical effects and antivenom dosing in brown snake (Pseudonaja spp.) envenoming--Australian snakebite project (ASP-14). PloS One, 7(12), 53188. doi: 10.1371/journal.pone.0053188*
4. *Anderson, V. E., Gerardo, C. J., & Rapp-Olsson, M. (2018). Early administration of Fab antivenom resulted in faster limb recovery in copperhead snake envenomation patients. Clin. Toxicol., 1–6.*
5. *Anil, A., Surjit, S., & Ashish, B. (2010). Role of neostigmine and polyvalent antivenom in Indian common krait (Bungarus caeruleus) bite. J. Infect. Publ. Health, 3(2), 83–87. doi: 10.1016/j.jiph.2010.01.002*
6. *Ariaratnam, C. A., Sheriff, M. H., & Theakston, R. D. A. (2008). Distinctive epidemiologic and clinical features of common krait (Bungarus caeruleus) bites in Sri Lanka. Am. J. Trop. Med. Hyg., 79(3), 458–462.*
7. *Ariaratnam, C. A., Thuraisingam, V., & Kularatne, S. A. M. (2008). Frequent and potentially fatal envenoming by hump-nosed pit vipers (Hypnale hypnale and H. nepa) in Sri Lanka: lack of effective antivenom. Trans. R. Soc. Trop.*

Med. Hyg., 102, 1120–1126. doi: 10.1016/j.trstmh.2008.03.023

8. *Ariaratnam, C. A., Sheriff, M. H. R., & Arambepola, C. (2009). Syndromic approach to treatment of snake bite in Sri Lanka based on results of a prospective national hospital-based survey of patients envenomed by identified snakes. Am. J. Trop. Med. Hyg., 81, 725–731. doi: 10.4269/ajtmh.2009.09-0225*
9. *Gutiérrez, J. M., Warrell, D. A., Williams, D. J., Jensen, S., Brown, N., Calvete, J. J., ... et al. (2013). The need for full integration of snakebite envenoming within a global strategy to combat the neglected tropical diseases: The way forward. PLoS Neglected Tropical Diseases, 7(6), 7-9.*
10. *Gutiérrez, J. M., Solano, G., Pla, D., Herrera, M., Segura, Á., Villalta, M., et al. (2013). Assessing the preclinical efficacy of antivenoms: From the lethality neutralization assay to antivenomics. Toxicon, 69, 168-179. [Internet]. DOI: 10.1016/j.toxicon.2012.11.016*
11. *Williams, D. J., Faiz, M. A., Abela-Ridder, B., Ainsworth, S., Bulfone, T. C., Nickerson, A. D., et al. (2019). Strategy for a globally coordinated response to a priority neglected tropical disease: Snakebite envenoming. PLoS Neglected Tropical Diseases, 13(2), 12-14.*
12. *Alirol, E., Sharma, S. K., Bawaskar, H. S., Kuch, U., & Chappuis, F. (2010). Snake bite in South Asia: A review. PLoS Neglected Tropical Diseases, 4(1), 1-9.*
13. *Leon, G., Vargas, M., Segura, A., Herrera, M., Villalta, M., & Sanchez, A. (2018). Current technology for the industrial manufacture of snake antivenoms. Toxicon, 151, 63-73.*
14. *Habib, A., & Brown, N. (2018). The snakebite problem and antivenom crisis from a health-economic perspective. Toxicon, 150, 115-123.*
15. *Alirol, E., Lechevalier, P., Zamatto, F., Chappuis, F., Alcoba, G., & Potet, J. (2015). Antivenoms for snakebite envenoming: What is in the research pipeline? PLoS Neglected Tropical Diseases, 9(9), 1-11.*
16. *Harrison, R. A. (2004). Development of venom toxin-specific antibodies by DNA immunisation: Rationale and strategies to improve therapy of viper envenoming. Vaccine, 22(13-14), 1648-1655.*
17. *Casewell, N. R., Cook, D. A. N., Wagstaff, S. C., Nasidi, A., Durfa, N., & Harrison, R. A., et al. (2010). Pre-clinical assays predict pan-African Echis viper efficacy for a species-specific Antivenom. PLoS Neglected Tropical Diseases, 4(10), 1-8.*
18. *Theakston, R. D. G., & Laing, G. D. (2014). Diagnosis of snakebite and the importance of immunological tests in venom research. Toxins (Basel), 6, 1667-1695.*
19. *Williams, H. F., Layfield, H. J., Vallance, T., Patel, K., Bicknell, A. B., Trim, S. A., et al. (2019). The urgent need to develop novel strategies for the diagnosis and treatment of snakebites. Toxins (Basel), 11(363), 1-29.*
20. *Pucca, M. B., Cerni, F. A., Janke, R., Bermúdez-Méndez, E., Ledsgaard, L., Barbosa, J. E., et al. (2019). History of envenoming therapy and current perspectives. Frontiers in Immunology, 10(1598), 1-13.*